TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07748533: A Multi-center, Open-label, Single-arm Phase I Study to Assess the Safety, and Tolerability of HY001N Cell Injection in Patients With Autoimmune Hemolytic Anemia After Failure of Three or More Lines of Therapy

Sponsor: Juventas Cell Therapy Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,090,820

Rescue Site Savings

+$3,354,780

Unlock Full NCT07748533 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07748533 Rescue Dossier →